Wayne R. Godfrey

5.6k total citations · 2 hit papers
45 papers, 3.6k citations indexed

About

Wayne R. Godfrey is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Wayne R. Godfrey has authored 45 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 18 papers in Oncology and 17 papers in Genetics. Recurrent topics in Wayne R. Godfrey's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (17 papers) and CAR-T cell therapy research (15 papers). Wayne R. Godfrey is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (17 papers) and CAR-T cell therapy research (15 papers). Wayne R. Godfrey collaborates with scholars based in United States, United Kingdom and France. Wayne R. Godfrey's co-authors include Sheri Miraglia, David Buck, Bruce R. Blazar, Roger A. Warnke, Edmund K. Waller, Jeannine T. Holden, Kristin A. Atkins, Robert A. Bray, Stephen B. Porter and Edgar G. Engleman and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Wayne R. Godfrey

43 papers receiving 3.5k citations

Hit Papers

A Novel Five-Transmembrane Hematopoietic Stem Cell Antige... 1997 2026 2006 2016 1997 2010 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization, and Molecular Cloning
    1997 779 citations Sheri Miraglia, Wayne R. Godfrey et al. Blood profile →
  2. Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
    2010 727 citations Wayne R. Godfrey et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wayne R. Godfrey United States 18 1.8k 1.4k 1.0k 628 497 45 3.6k
Johanna Olweus Norway 26 1.8k 1.0× 1.5k 1.1× 1.3k 1.3× 534 0.9× 241 0.5× 61 3.9k
Régis Costello France 33 2.0k 1.2× 1.3k 1.0× 872 0.9× 363 0.6× 270 0.5× 153 3.9k
Stefan Einhorn Sweden 36 1.4k 0.8× 1.3k 0.9× 1.1k 1.1× 648 1.0× 206 0.4× 107 3.4k
Claudia Voena Italy 29 735 0.4× 1.2k 0.9× 1.4k 1.4× 427 0.7× 581 1.2× 57 3.2k
Martina Rudelius Germany 31 590 0.3× 902 0.7× 1.1k 1.1× 512 0.8× 311 0.6× 89 3.0k
Simon D. Wagner United Kingdom 33 1.2k 0.7× 676 0.5× 981 1.0× 599 1.0× 166 0.3× 104 3.0k
Lydia Visser Netherlands 36 1.6k 0.9× 1.3k 1.0× 1.0k 1.0× 545 0.9× 250 0.5× 130 3.8k
Edward D. Ball United States 31 1.3k 0.7× 1.2k 0.9× 1.2k 1.2× 364 0.6× 189 0.4× 176 3.5k
Scott Ely United States 28 674 0.4× 1.6k 1.2× 1.3k 1.3× 737 1.2× 331 0.7× 89 3.4k
Rajat Bannerji United States 23 1.4k 0.8× 1.6k 1.2× 965 1.0× 521 0.8× 491 1.0× 58 3.0k

Countries citing papers authored by Wayne R. Godfrey

Since Specialization
Citations

This map shows the geographic impact of Wayne R. Godfrey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wayne R. Godfrey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wayne R. Godfrey more than expected).

Fields of papers citing papers by Wayne R. Godfrey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wayne R. Godfrey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wayne R. Godfrey. The network helps show where Wayne R. Godfrey may publish in the future.

Co-authorship network of co-authors of Wayne R. Godfrey

This figure shows the co-authorship network connecting the top 25 collaborators of Wayne R. Godfrey. A scholar is included among the top collaborators of Wayne R. Godfrey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wayne R. Godfrey. Wayne R. Godfrey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Budimir, Natalija, Simon Shenhav, Hua Wu, et al.. (2022). 1325 Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T Cell engager for treatment of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts. A1376–A1376. 7 indexed citations
2.
Budimir, Natalija, Lina Ma, Simon Shenhav, et al.. (2022). 1123 Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors. Regular and Young Investigator Award Abstracts. A1167–A1167. 3 indexed citations
3.
Coutré, Steven, John P. Leonard, Christopher R. Flowers, et al.. (2015). Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).. Journal of Clinical Oncology. 33(15_suppl). 8532–8532. 4 indexed citations
4.
Wagner‐Johnston, Nina D., Ajay K. Gopal, Brad S. Kahl, et al.. (2014). Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. Journal of Clinical Oncology. 32(15_suppl). e19554–e19554. 7 indexed citations
5.
6.
McLeod, David G., George W. Adams, Marc Gittleman, et al.. (2013). Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 31(6_suppl). 193–193.
7.
Benson, Don M., Brad S. Kahl, Richard R. Furman, et al.. (2013). Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).. Journal of Clinical Oncology. 31(15_suppl). 8526–8526. 12 indexed citations
8.
9.
Leonard, John P., Pier Luigi Zinzani, Wojciech Jurczak, et al.. (2013). A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).. Journal of Clinical Oncology. 31(15_suppl). TPS8617–TPS8617. 6 indexed citations
10.
Shi, Lingfang, Wayne R. Godfrey, Joseph Lin, Guohua Zhao, & Peter N. Kao. (2007). NF90 regulates inducible IL-2 gene expression in T cells. The Journal of Experimental Medicine. 204(5). 971–977. 71 indexed citations
11.
Shi, Lingfang, Guohua Zhao, Daoming Qiu, et al.. (2005). NF90 Regulates Cell Cycle Exit and Terminal Myogenic Differentiation by Direct Binding to the 3′-Untranslated Region of MyoD and p21WAF1/CIP1 mRNAs. Journal of Biological Chemistry. 280(19). 18981–18989. 82 indexed citations
12.
Li, Lequn, et al.. (2005). CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood. 106(9). 3068–3073. 117 indexed citations
13.
Godfrey, Wayne R., et al.. (2004). In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures. Blood. 104(2). 453–461. 237 indexed citations
14.
Pippig, Susanne, Claudia Peña-Rossi, James P. Long, et al.. (1999). Robust B Cell Immunity but Impaired T Cell Proliferation in the Absence of CD134 (OX40). The Journal of Immunology. 163(12). 6520–6529. 144 indexed citations
15.
Miraglia, Sheri, Wayne R. Godfrey, & David Buck. (1998). A Response to AC133 Hematopoietic Stem Cell Antigen: Human Homologue of Mouse Kidney Prominin or Distinct Member of a Novel Protein Family?. Blood. 91(11). 4390–4391. 46 indexed citations
16.
Miraglia, Sheri, Wayne R. Godfrey, Kristin A. Atkins, et al.. (1997). A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization, and Molecular Cloning. Blood. 90(12). 5013–5021. 779 indexed citations breakdown →
17.
Weinberg, Andrew D., Dennis Bourdette, Timothy J. Sullivan, et al.. (1996). Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis. Nature Medicine. 2(2). 183–189. 130 indexed citations
18.
Kapp, Judith A., Carl W. Pierce, David R. Webb, et al.. (1995). Characterization of the epitope recognized by a mAb that reacts differentially with murine suppressor T cells. International Immunology. 7(8). 1319–1330. 6 indexed citations
19.
Godfrey, Wayne R., et al.. (1994). Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.. The Journal of Experimental Medicine. 180(2). 757–762. 240 indexed citations
20.
Young, Robert L., et al.. (1983). Runaways: A Review of Negative Consequences. Family Relations. 32(2). 275–275. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johanna Olweus Breakdown of academic impact, for papers by Régis Costello Breakdown of academic impact, for papers by Stefan Einhorn Breakdown of academic impact, for papers by Claudia Voena Breakdown of academic impact, for papers by Martina Rudelius Breakdown of academic impact, for papers by Simon D. Wagner Breakdown of academic impact, for papers by Lydia Visser Breakdown of academic impact, for papers by Edward D. Ball Breakdown of academic impact, for papers by Scott Ely Breakdown of academic impact, for papers by Rajat Bannerji
Rankless by CCL
2026